Gene · 386653
Papers2,753
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,753
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Aeroallergens in Atopic Dermatitis and Chronic Urticaria. | Curr Allergy Asthma Rep | 2026 | 42133244 | PubTator, text mining | PubMed |
| Off-label Use of Nemolizumab to Address Pruritic Skin Disease: A Case Series in Dermatomyositis Patients. | J Clin Rheumatol | 2026 | 42119021 | PubTator, text mining | PubMed |
| Rethinking interleukin-31: A neuroimmune orchestrator of itch beyond Th2 immunity. | Allergol Int | 2026 | 42091372 | PubTator, text mining | PubMed |
| Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor-Modulating Agent in the Treatment of Atopic Dermatitis. | J Dermatol | 2026 | 42057395 | PubTator, text mining | PubMed |
| Inflammatory Cytokine Genotypic Markers and Ovarian Cancer Risk. | Anticancer Res | 2026 | 42049359 | PubTator, text mining | PubMed |
| Possible involvement of interleukin-31 in pruriginosa-type recessive dystrophic epidermolysis bullosa: a positive response to nemolizumab. | Clin Exp Dermatol | 2026 | 42047108 | PubTator, text mining | PubMed |
| A descriptive multilevel analysis associating COVID-19 with polymyositis: from genetic markers and candidate mediators to clinical hematological profiles. | Front Med (Lausanne) | 2026 | 42040572 | PubTator, text mining | PubMed |
| Mechanistic Insights Into OSM and IL-31 in Primary Localized Cutaneous Amyloidosis: A Narrative Review. | Int J Dermatol | 2026 | 42029085 | PubTator, text mining | PubMed |
| Distinct inflammatory biomarkers associated with rheumatological outcomes in chronic chikungunya disease. | Sci Rep | 2026 | 41997930 | PubTator, text mining | PubMed |
| SARS-CoV-2 infection during the first trimester leads to profound immune dysregulation at the maternal-fetal interface despite limited virus detection in placental tissues. | Nat Commun | 2026 | 41974725 | PubTator, text mining | PubMed |
| Targeting the JAK/STAT pathway in atopic dermatitis. | Front Immunol | 2026 | 41972174 | PubTator, text mining | PubMed |
| Bioelectric Profiling of Atopic Dermatitis: From Molecular Barrier Defects to Closed-Loop Theranostic Strategies. | Exp Dermatol | 2026 | 41969232 | PubTator, text mining | PubMed |
| Nemolizumab for Lichen Amyloidosis With Serial Serum Interleukin-31 Levels: A Case Report. | J Dermatol | 2026 | 41964247 | PubTator, text mining | PubMed |
| Evaluation of IL-31 and IL-31RA Expression in Lichen Planopilaris: A Retrospective Immunohistochemistry Study. | J Cutan Pathol | 2026 | 41952360 | PubTator, text mining | PubMed |
| Skin Barrier Dysfunction in Contact and Atopic Dermatitis: A Comparative Review. | Allergy Asthma Immunol Res | 2026 | 41914526 | PubTator, text mining | PubMed |
| Analysis of corneal biomechanical characteristics and clinical correlations in children with dust mite-allergic conjunctivitis. | Sci Rep | 2026 | 41896630 | PubTator, text mining | PubMed |
| A λ-Carrageenan-Enriched Sulfated Galactan from Gigartina radula Attenuates Atopic Dermatitis via Coordinated Anti-Inflammatory and Immunomodulatory Mechanisms. | Mar Drugs | 2026 | 41892978 | PubTator, text mining | PubMed |
| Enigmatic Role of IL-31 in the Itch and Inflammation of Vernal Keratoconjunctivitis. | Juntendo Med J | 2026 | 41859225 | PubTator, text mining | PubMed |
| Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab. | JID Innov | 2026 | 41853463 | PubTator, text mining | PubMed |
| What is new on the horizon for the biologics world: New kids of the block - WAO state of art. | World Allergy Organ J | 2026 | 41853324 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/386653/papers?page=3